ArticleBulletin of experimental biology and medicine2023
Expression of ADK-S and ADK-L Isoforms and Their Association with CD39/CD73/A2aR in Colorectal Cancer.
Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.Molecular neurobiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The level of mRNA of the long (L) and short (S) isoforms of adenosine kinase (ADK) was analyzed in patients with colorectal cancer (CRC). ADK is required to convert adenosine (ADO) to AMP. It was shown that tumor and normal colon tissues (n=13) do not differ in the level of ADK-S and ADK-L mRNA. At the same time, the level of ADK-S mRNA (tumor: p=0.0214, normal: p=0.005) in the colon tissue was lower than in the blood of CRC patients (n=20), and the level of ADK-L mRNA (tumor: p=0.007, normal: p=0.024), on the contrary, was higher. A negative correlation was found between the level of ADK-S mRNA and the level of A2aR mRNA in both tumor and normal tissues (p=0.018 and p=0.0014, respectively). In the tumor tissue, a positive correlation was shown between ADK-L and CD73 mRNA levels (p=0.017). The obtained data indicate the association ADK with the expression of CD39/CD73/A2aR in CRC patients. In this regard, the effect of recombinant ADK on the expression of CD39 and CD73 ectonucleotidase by T cells in vitro was analyzed. In a culture of peripheral blood mononuclear cells isolated from the blood of 5 healthy donors, ADK did not abolish the inhibitory effect on the expression of CD39 and CD73 by CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.